All In Biotech

BLA 125320 · Amgen

Prolia

Denosumab · Subcutaneous · RANK Ligand Inhibitor

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Jun 1, 2010

Approved uses

11

Original approval plus efficacy supplements

Registered trials

287

81 Phase 3, 26 recruiting

FAERS reports

203,628

111,298 serious, 26,093 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following Prolia administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported [see Warnings and Precautions (5.1) ] . The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients [see Warnings and Precautions (5.1) ] . Prior to initiating Prolia in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Prolia in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD [see Dosage and Administration (2.2) and Warnings and...

What it is approved for

From the label in effect Jun 26, 2026.

Prolia is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Prolia is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Prolia is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on...

Mechanism: Prolia binds to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. Prolia prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone.

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • PROLIA · DENOSUMAB 60MG/ML · INJECTABLE, SUBCUTANEOUS · Prescription
  • XGEVA · DENOSUMAB 70MG/ML · INJECTABLE, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Denosumab" as an intervention, any sponsor and status, largest first.

All 287 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use36,806
  • death20,597
  • arthralgia8,975
  • osteonecrosis of jaw8,703
  • fatigue7,855
  • pain in extremity7,063
  • pain7,019
  • back pain6,993
  • nausea5,551
  • diarrhoea5,433
  • fall5,380
  • rash4,374

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081
20093
2010146
20111,755
20125,568
20137,360
201411,624
201512,375
201620,402
201733,839
201833,692
201911,455
202010,399
202110,073
20229,831
202310,693
20249,318
20257,953
20267,141

Recalls

2 FDA enforcement reports for this application.

  • Apr 21, 2025 · Class II · Ongoing

    CGMP Deviations; potential temperature excursions due to transit delays

  • Sep 17, 2013 · Class II · Terminated

    Presence of Particulate Matter: Visible cellulose fibers were observed in a small number of prefilled syringes during a routine quality examination.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Prolia (Denosumab)

2024 spending

$772M

Beneficiaries

284,965

450,858 claims

Per beneficiary

$2,709

$1,711.38 per unit

View as table
YearSpending
2020$369,123,843
2021$439,589,886
2022$546,633,606
2023$673,286,887
2024$771,837,558

Part D: Xgeva (Denosumab)

2024 spending

$55.8M

Beneficiaries

3,495

17,654 claims

Per beneficiary

$15,974

$1,850.82 per unit

View as table
YearSpending
2020$31,600,873
2021$31,888,556
2022$38,647,365
2023$46,309,173
2024$55,828,366

Part B: Prolia* (Denosumab*) · HCPCS J0897

2024 spending

$2.43B

Beneficiaries

700,724

1,339,338 claims

Per beneficiary

$3,469

2024 ASP limit $26.02 per unit

View as table
YearSpending
2020$1,627,019,055
2021$1,780,811,015
2022$2,003,916,528
2023$2,190,209,346
2024$2,430,935,308

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 725 on PubMed

Sponsor: Amgen · Also marketed as Xgeva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.